The risk of seasonal and pandemic influenza: Prospects for control

Clinical Infectious Diseases

Volumn 48, Issue SUPPL. 1, 2009, Pages

  Monto, Arnold S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

HUMAN; INFECTION CONTROL; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; MORBIDITY; MORTALITY; NONHUMAN; PANDEMIC; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTIVIRAL AGENTS; CHEMOPREVENTION; COMMUNICABLE DISEASE CONTROL; DISEASE OUTBREAKS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; RISK ASSESSMENT;

EID: 57749088512     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/591853     Document Type: Review

References (35)

1. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40.
2. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86.
3. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7:658-66.
4. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-6):1-54.
5. Ohmit SE, Arden NH, Monto AS. Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic. J Am Geriatr Soc 1999; 47:165-71.
6. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985; 253:1136-9.
7. Arden NH, Patriarca PA, Fasano MB, et al. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home. Arch Intern Med 1988; 148:865-8.
8. Centers for Disease Control and Prevention. Update: influenza activity - United States and worldwide, 2006-07 season, and composition of the 2007-08 influenza vaccine. MMWR Morb Mortal Wkly Rep 2007; 56:789-94.
9. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998; 148:1094-102.
10. Jordan EO. The nature and course of an attack. In: Epidemic influenza: a survey. Chicago: American Medical Association, 1927:257-304. Available at: http://link.library.utoronto.ca/booksonline/digobject.cfm?Idno= B9900339&CFID=8497833&CFTOKEN=92656341#jpeg. Accessed 4 September 2007.
11. Mak TK, Mangtani P, Leese J, Watson JM, Pfeifer D. Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis 2008; 8:44-52.
12. Zaman Z, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359:1555-64.
13. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 344:889-986.
14. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7:658-66.
15. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis 1970; 122:16-25.
16. Infectious Diseases Branch, Ontario Ministry of Health and Long-Term Care. Ontario's universal influenza immunization program (UIIP): prepared for Options for the Control of Influenza VI Conference (Toronto). Toronto: Ontario Ministry of Health and Long-Term Care, 2007.
17. Treanor JJ, Betts RF. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Vaccine 1998; 16:1756-60.
18. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-96.
19. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. Influenza Special Investigations Team. N Engl J Med 2005; 353:2559-67.
20. Louie JK, Schechter R, Honarmand S, et al. Severe pediatric influenza in California, 2003-2005: implications for immunization recommendations. Pediatrics 2006; 117:e610-8.
21. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860-9.
22. Ashkenazi S, Vertruyen A, Arístegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870-9.
23. Infectious Diseases Society of America (IDSA). Pandemic and seasonal influenza principles for US action. Alexandria, VA: IDSA, 2007. Available at: http://www.idsociety.org/WorkArea/showcontent.aspx?id=5728. Accessed 10 January 2008.
24. Dauer CC, Serfling RE. Mortality from influenza: 1957-1958 and 1959-1960. Am Rev Respir Dis 1961; 83(Suppl 2):15-28.
25. Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine 2003; 21:1762-8.
26. Centers for Disease Control and Prevention. Interim pre-pandemic planning guidance: community strategy for pandemic influenza mitigation in the United States - early, targeted, layered use of nonpharmaceutical interventions. Washington, DC: US Department of Health and Human Services, 2007. Available at: http://www.pandemicflu.gov/plan/community/community_mitigation. pdf. Accessed 6 September 2007.
27. Markel H, Lipman HB, Navarro JA, et al. Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic. JAMA 2007; 298:644-54.
28. ClinicalTrials.gov. Intervention study of face mask and hand sanitizer to reduce influenza transmission [NCT00490633]. 22 June 2007. Available at: http://clinicaltrials.gov. Accessed 20 November 2007.
29. ClinicalTrials.gov. Reducing influenza among university students, University of California at Berkeley [NCT00448773]. 16 March 2007. Available at: http://clinicaltrials.gov. Accessed 20 November 2007.
30. ClinicalTrials.gov. A randomized, controlled, unblinded, clinical trial of the acceptability and efficacy of non-pharmaceutical methods in preventing spread of influenza within the family [NCT00410176]. 11 December 2006. Available at: http://clinicaltrials.gov. Accessed 20 November 2007.
31. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186:1582-8.
32. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. Oseltamivir Post Exposure Prophylaxis Investigator Group. JAMA 2001; 285:748-54.
33. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000; 343:1282-9.
34. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189:440-9.
35. Department of Health and Human Services. Pandemic planning update IV: a report from Secretary Michael O. Leavitt. Washington, DC: US Department of Health and Human Services, 2007. Available at: http://www.pandemicflu. gov/plan/panflureport4.pdf. Accessed 27 July 2007.